Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 30, 2025 08:58 ET | Source: Research and Markets

United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "United States Vitiligo Market Report by Diseases Type, Treatment Type, End User, Regions and Company Analysis, 2025-2033" report has been added to ...
August 14, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment...
August 12, 2025 04:04 ET | Source: Research and Markets

Vitiligo Treatment Strategic Market Research Report 2025-2030 | Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Vitiligo Treatment...
August 08, 2025 16:35 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
May 28, 2025 09:20 ET | Source: Research and Markets

Vitiligo Market Growth Trends and Forecast Report 2025-2033 - Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access

Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The...
May 14, 2025 16:15 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Second Quarter Earnings Release 2025
May 07, 2025 00:10 ET | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled
April 28, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
March 03, 2025 21:17 ET | Source: Clinuvel Pharmaceuticals Limited

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11,...